YieldMax AI & Tech Portfolio Option Income ETF vs Novartis AG — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.75 (market cap $135.69M), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Novartis AG is far larger — about 1979.3× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Novartis AG pays a 3.31% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 60 Days and Novartis AG for 82 Days on average.
| GPTY | NVS | |
|---|---|---|
Market Cap | $135.69M | $268.57B |
Volume | 97,442 | 1,532,573 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $168.62 |
52-Week Low | $34.73 | $121.80 |
Typical Hold Time | 60 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →